3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Carcinoma, Non-Small-Cell Lung
501
Neoplasms
304
Breast Neoplasms
298
Colorectal Neoplasms
230
Neoplasm Metastasis
196
Prostatic Neoplasms
175
Ovarian Neoplasms
173
Lung Neoplasms
160
Multiple Myeloma
159
Recurrence
134
Melanoma
125
Pancreatic Neoplasms
116
Squamous Cell Carcinoma of Head and Neck
105
Stomach Neoplasms
103
Leukemia, Myeloid, Acute
102
Endometrial Neoplasms
102
Small Cell Lung Carcinoma
89
Leukemia, Lymphocytic, Chronic, B-Cell
87
Triple Negative Breast Neoplasms
85
Lymphoma, Non-Hodgkin
85
Carcinoma, Renal Cell
83
Carcinoma, Hepatocellular
79
Urinary Bladder Neoplasms
77
Lymphoma, Large B-Cell, Diffuse
74
Lymphoma, Follicular
68
Advanced Solid Tumors
66
Parkinson Disease 4, Autosomal Dominant Lewy Body
62
Lymphoma
62
Glioblastoma
59
Head and Neck Neoplasms
57
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Amyloid Neuropathies, Familial
×
90 days
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled